Total Payments
$154,470
2024 Payments
$6,980
Companies
10
Transactions
173
Medicare Patients
2,046
Medicare Billing
$242,736
Payment Breakdown by Category
Other$105,520 (68.3%)
Consulting$32,047 (20.7%)
Travel$12,270 (7.9%)
Food & Beverage$4,632 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105,520 | 51 | 68.3% |
| Consulting Fee | $32,047 | 30 | 20.7% |
| Travel and Lodging | $12,270 | 37 | 7.9% |
| Food and Beverage | $4,632 | 55 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $114,436 | 127 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $22,079 | 22 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $7,980 | 6 | $0 (2021) |
| ABBVIE INC. | $5,852 | 7 | $0 (2023) |
| BeiGene USA, Inc. | $1,650 | 1 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,208 | 3 | $0 (2017) |
| GlaxoSmithKline, LLC. | $975.00 | 1 | $0 (2021) |
| Stemline Therapeutics Inc. | $151.59 | 4 | $0 (2024) |
| Foundation Medicine, Inc. | $125.09 | 1 | $0 (2017) |
| ARRAY BIOPHARMA INC | $13.61 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,980 | 14 | AstraZeneca Pharmaceuticals LP ($5,120) |
| 2023 | $12,028 | 13 | AstraZeneca Pharmaceuticals LP ($6,630) |
| 2022 | $3,153 | 7 | ABBVIE INC. ($1,650) |
| 2021 | $16,198 | 12 | AstraZeneca Pharmaceuticals LP ($9,735) |
| 2020 | $10,574 | 9 | Jazz Pharmaceuticals Inc. ($6,090) |
| 2019 | $49,580 | 53 | Genentech USA, Inc. ($49,580) |
| 2018 | $18,695 | 22 | Genentech USA, Inc. ($18,695) |
| 2017 | $37,262 | 43 | Genentech USA, Inc. ($35,929) |
All Payment Transactions
173 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $252.50 | General |
| Category: BioOncology | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,340.00 | General |
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,675.00 | General |
| 11/04/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $36.60 | General |
| Category: Oncology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $5.28 | General |
| 09/04/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $505.00 | General |
| Category: BioOncology | ||||||
| 09/03/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $505.00 | General |
| Category: BioOncology | ||||||
| 07/17/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $505.00 | General |
| 03/06/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 02/14/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 01/22/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $41.59 | General |
| Category: Oncology | ||||||
| 11/07/2023 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $505.00 | General |
| 11/01/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 10/20/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| Category: Oncology | ||||||
| 09/19/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Oncology | ||||||
| 09/08/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $40.12 | General |
| Category: Oncology | ||||||
| 08/17/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $332.22 | General |
| Category: ONCOLOGY | ||||||
| 08/17/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 07/27/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 04/17/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $33.28 | General |
| Category: Oncology | ||||||
| 04/13/2023 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $455.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 493 | 868 | $253,208 | $65,180 |
| 2022 | 9 | 526 | 882 | $257,192 | $67,617 |
| 2021 | 10 | 574 | 841 | $232,514 | $64,998 |
| 2020 | 10 | 453 | 768 | $174,158 | $44,942 |
Total Patients
2,046
Total Services
3,359
Medicare Billing
$242,736
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 121 | 299 | $92,299 | $22,635 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 173 | 269 | $71,080 | $13,723 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 110 | $41,842 | $12,543 | 30.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $15,869 | $4,542 | 28.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 34 | $11,014 | $3,556 | 32.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 34 | 51 | $6,417 | $2,699 | 42.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $7,155 | $2,348 | 32.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 28 | $4,756 | $1,781 | 37.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 14 | 18 | $2,776 | $1,353 | 48.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 309 | $93,627 | $23,731 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 167 | 271 | $70,460 | $13,988 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 70 | 116 | $43,268 | $13,718 | 31.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $9,702 | $3,302 | 34.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 21 | $9,702 | $3,279 | 33.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 54 | 63 | $7,749 | $2,945 | 38.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 23 | 23 | $7,337 | $2,523 | 34.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $6,533 | $1,665 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 18 | $5,454 | $1,367 | 25.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 20 | $3,360 | $1,099 | 32.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 139 | 275 | $83,325 | $22,131 | 26.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 168 | 253 | $65,780 | $13,372 | 20.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 70 | $26,110 | $8,386 | 32.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 52 | 52 | $15,884 | $5,565 | 35.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 79 | 103 | $12,669 | $4,947 | 39.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 19 | $8,583 | $3,125 | 36.4% |
About Dr. Randall Ingham, M.D
Dr. Randall Ingham, M.D is a Internal Medicine healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2010. The National Provider Identifier (NPI) number assigned to this provider is 1215257027.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Randall Ingham, M.D has received a total of $154,470 in payments from pharmaceutical and medical device companies, with $6,980 received in 2024. These payments were reported across 173 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($105,520).
As a Medicare-enrolled provider, Ingham has provided services to 2,046 Medicare beneficiaries, totaling 3,359 services with total Medicare billing of $242,736. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Providence, RI
- Active Since 06/03/2010
- Last Updated 06/03/2010
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1215257027
Products in Payments
- TECENTRIQ (Biological) $75,584
- Alecensa (Biological) $18,548
- ROZLYTREK (Biological) $13,260
- IMFINZI (Biological) $10,613
- ZEPZELCA (Drug) $7,980
- VENCLEXTA (Drug) $5,852
- Tarceva (Drug) $2,522
- TAGRISSO (Drug) $2,430
- LYNPARZA (Drug) $2,220
- BRUKINSA (Drug) $1,650
- Tecentriq (Biological) $1,263
- Stivarga (Drug) $1,208
- CALQUENCE (Drug) $1,050
- Truqap (Drug) $525.00
- Orserdu (Drug) $151.59
- FOUNDATIONONE (Device) $125.09
- GAZYVA (Biological) $87.07
- LORBRENA (Drug) $13.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Providence
Farah Moustafa, Md, MD
Internal Medicine — Payments: $50,984
Internal Medicine $50,984
Monica Dhakar, M.d, M.D
Internal Medicine — Payments: $47,405
Internal Medicine $47,405
Hajra Awwab, Md, MD
Internal Medicine — Payments: $41,418
Internal Medicine $41,418
Richard Ruggieri, M.d, M.D
Internal Medicine — Payments: $36,352
Internal Medicine $36,352
Dr. Peter Barth, M.d, M.D
Internal Medicine — Payments: $29,192
Internal Medicine $29,192
Jeffrey Lawrence, M.d, M.D
Internal Medicine — Payments: $23,037
Internal Medicine $23,037